Megan Garlapow, PhD

Megan Garlapow, PhD, is the principal and owner of The Line Medical Communications, LLC, where she brings extensive experience in medical communications across diverse therapeutic areas. Dr Garlapow earned her BA in biology from the University of Chicago and her PhD in genetics from North Carolina State University. With a strong background in biomedical science and genetics, Dr Garlapow has held key roles in medical education and clinical genetics and genomics, where she honed her skills in developing strategic proposals, securing funding, delivering high-quality educational content, and composing engaging medical journalism pieces.

All articles by Megan Garlapow, PhD

Study compares bladder-sparing and cystectomy outcomes in bladder cancer

Bladder preservation significantly reduced cancer-specific deaths at both two and five years compared with bladder removal in bladder cancer.
Targeted drug delivery system Erda-iDRS shows lasting benefits in bladder cancer

Erda-iDRS uses a device in the bladder to release erdafitinib, and achieved an 89% complete response rate in intermediate-risk disease.
Study identifies target that may overcome drug resistance in bladder cancer

A protein called LTBP1 appears to drive resistance to cisplatin in bladder cancer and is linked to more advanced disease and poorer survival.
Study identifies glycolysis genes that influence bladder cancer risk

A new study suggests that certain genes involved in how cells process sugar for energy may influence the risk of bladder cancer,
Study shows tumor DNA guides safer bladder-sparing treatment

Nearly seven in 10 patients with bladder cancer with a complete response were alive with their bladder intact at three years.
Living in a disadvantaged area raises bladder cancer death risk

Where a patient lives and the resources in that neighborhood can influence the risk of dying from bladder cancer over time.
Gene analysis highlights need for sex-specific bladder cancer treatment

A study found that hundreds of genes in early-stage bladder cancer tumors behave differently depending on a patient’s sex.
Noninvasive test accurately detects non-muscle invasive bladder cancer

The utLIFE-UC assay is a noninvasive test that can accurately diagnose non-muscle invasive bladder cancer, a recent study showed.